Holen Sie sich die Stockscreener-App
189.09
0.49%
-0.98
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$190.07
Offen:
$189.46
24-Stunden-Volumen:
144.18K
Relative Volume:
0.12
Marktkapitalisierung:
$27.75B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
21.47
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
+7.46%
1M Leistung:
+3.00%
6M Leistung:
+26.03%
1J Leistung:
+60.06%
1-Tages-Spanne:
$188.49
$190.32
1-Wochen-Bereich:
$175.69
$192.75
52-Wochen-Spanne:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
189.12 | 27.29B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
919.00 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
229.58 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
201.17 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
195.95 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.36 | 278.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
JPMorgan Adjusts Price Target on Biogen to $185 From $175, Maintains Neutral Rating - marketscreener.com
Jim Cramer Says “I Got to Reopen the File on Biogen” - Yahoo Finance
Biogen Loses Multiple Sclerosis Treatment Patent On Appeal - Law360
Biogen strengthens global pipeline with $100m TJ biopharma partnership - BioXconomy
Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027 - Proactive financial news
Biogen Stock Analysis: Recent Gains Mask Long-Term Financial WeaknessNews and Statistics - IndexBox
BIOGEN Tax Provision: $-264 Mil | Fairly Valued - GuruFocus
UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts - Investing.com Canada
Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says - marketscreener.com
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade? - Yahoo Finance
BIIB Upgraded by UBS -- Price Target Raised to $225 - GuruFocus
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline - Yahoo Finance
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Biogen, Cava Group, GitLab, Halliburton, Qualcomm, Seagate, Toast, and More - Yahoo Finance
UBS Upgrades Biogen to Buy From Neutral, Adjusts Price Target to $225 From $185 - marketscreener.com
Analyst recommendations: Albemarle, Biogen, Qualcomm, Twilio, Lyondellbasell… - marketscreener.com
TJ Biopharma enters into agreement with Biogen for Felzartamab assets in Greater China Region - BioSpectrum Asia
UBS upgrades Biogen stock rating on pipeline catalysts, raises target to $225 - Investing.com
Biogen Inc. (BIIB)Secures Exclusive Global Felzartamab Rights via Greater China Licensing Deal, Shares RallyViral Trade Signals - UBND thành phố Hải Phòng
Biogen Inc. (BIIB) – Strategic Portfolio Review Signals Near-Term Earnings HeadwindsCommunity Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen - Yahoo Finance
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma - BioPharma APAC
Biogen amasses full felzartamab rights with $850M TJ deal - BioWorld News
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up - TradingView
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead - Yahoo Finance
Amyloid Setback: Future Possibilities For The Treatment Of Alzheimer's Disease - Seeking Alpha
Biogen gets worldwide development and commercialization rights to felzartamab - The Pharma Letter
Lobbying Update: $1,460,000 of BIOGEN lobbying was just disclosed - Quiver Quantitative
Biogen (BIIB) Stock Trades Up, Here Is Why - Yahoo Finance
Biogen Inc (BIIB) Shares Surge 3.4% -- What GF Score of 72 Tells Investors - GuruFocus
Biogen Inc. stock (US09062X1037): Is its neurology focus strong enough to drive new upside? - AD HOC NEWS
Biogen earnings preview: What to expect - MSN
Biogen (BIIB) Secures Exclusive Rights to Felzartamab in Greater China - GuruFocus
BIIB Upgraded by Wells Fargo -- Price Target Raised to $250 - GuruFocus
Biogen Earnings Preview: What to Expect - Barchart.com
Biogen to buy China rights to immune disease drug for up to $850M - Seeking Alpha
Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act? - 24/7 Wall St.
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma - Reuters
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region - Tirto.id
Biogen enters into agreement with TJ Biopharma for Felzartamab assets in the Greater China region - marketscreener.com
Biogen acquires China rights to felzartamab for up to $850M By Investing.com - Investing.com Canada
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region - Biogen
Biogen Enters Into Agreement With TJ Biopharma For Felzartamab Assets In The Greater China Region - marketscreener.com
Wells Fargo Upgrades Biogen to Overweight From Equalweight, Adjusts PT to $250 From $200 - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Navigating a 17% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Rating Balance Draws Nasdaq Composite Attention - Kalkine Media
Notable analyst calls this week: Tesla, Qualcomm and Biogen among top picks - Seeking Alpha
Understanding Momentum Shifts in (BIIB) - Stock Traders Daily
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Biogen secures FDA nod for higher dose of SMA drug Spinraza - MSN
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Viehbacher Christopher | President and CEO |
Feb 06 '26 |
Option Exercise |
0.00 |
24,461 |
0 |
36,548 |
| Singhal Priya | Head of Development |
Feb 06 '26 |
Option Exercise |
0.00 |
6,900 |
0 |
12,115 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 06 '26 |
Option Exercise |
0.00 |
8,725 |
0 |
21,016 |
| Kramer Robin | Chief Financial Officer |
Feb 06 '26 |
Option Exercise |
0.00 |
5,003 |
0 |
12,535 |
| Keeney Adam | Head of Corporate Development |
Feb 06 '26 |
Option Exercise |
0.00 |
5,080 |
0 |
6,875 |
| Izzar Rachid | Head of Global Product Strat. |
Feb 06 '26 |
Option Exercise |
0.00 |
6,889 |
0 |
11,786 |
| Grogan Jane | Head of Research |
Feb 06 '26 |
Option Exercise |
0.00 |
3,258 |
0 |
4,642 |
| Gregory Ginger | EVP, Human Resources |
Feb 06 '26 |
Option Exercise |
0.00 |
7,183 |
0 |
23,491 |
1.06%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):